Nuravax, Inc.
Nuravax is a pioneering biotech company focused on developing immunotherapies and vaccines for neurodegenerative diseases, especially Alzheimer's and Parkinson's. Utilizing their proprietary MultiTEP platform, they design highly specific vaccine therapies to target the root causes of neurological disorders, aiming to prevent and cure conditions like Alzheimer's and Parkinson's by inducing high antibody titers against pathological proteins. Their mission is to prevent and cure CNS disorders through innovative immunotherapy, with a focus on the elderly population, leveraging over two decades of research and collaborations with institutions like the Institute for Molecular Medicine and NIH.
Industries
Nr. of Employees
small (1-50)
Nuravax, Inc.
5270 California Ave., Suite 300, Irvine, CA 92617
Products
Amyloid-β DNA vaccine candidate
Plasmid-based vaccine candidate encoding amyloid-β epitope(s) intended to induce anti-amyloid antibody responses for preventive administration in at-risk populations.
Tau recombinant protein vaccine candidate
Recombinant protein vaccine targeting tau epitopes formulated with a potent adjuvant to generate anti-tau antibodies and evaluated in preclinical and early clinical studies.
Combined amyloid-β / tau recombinant vaccine candidate
Combined recombinant protein approach targeting both amyloid-β and tau epitopes to induce antibodies against multiple pathological targets concurrently.
α-Synuclein vaccine candidates (DNA and recombinant protein)
Vaccine designs targeting multiple B-cell epitopes of pathological α-synuclein available in DNA and recombinant protein formats and evaluated in preclinical models to reduce pathological burden and motor deficits.
mRNA vaccine candidate targeting amyloid-β
mRNA-format vaccine candidate encoding amyloid-β epitope(s) intended for preventive immunization and evaluated as part of a multi-modality development strategy.
Amyloid-β DNA vaccine candidate
Plasmid-based vaccine candidate encoding amyloid-β epitope(s) intended to induce anti-amyloid antibody responses for preventive administration in at-risk populations.
Tau recombinant protein vaccine candidate
Recombinant protein vaccine targeting tau epitopes formulated with a potent adjuvant to generate anti-tau antibodies and evaluated in preclinical and early clinical studies.
Combined amyloid-β / tau recombinant vaccine candidate
Combined recombinant protein approach targeting both amyloid-β and tau epitopes to induce antibodies against multiple pathological targets concurrently.
α-Synuclein vaccine candidates (DNA and recombinant protein)
Vaccine designs targeting multiple B-cell epitopes of pathological α-synuclein available in DNA and recombinant protein formats and evaluated in preclinical models to reduce pathological burden and motor deficits.
mRNA vaccine candidate targeting amyloid-β
mRNA-format vaccine candidate encoding amyloid-β epitope(s) intended for preventive immunization and evaluated as part of a multi-modality development strategy.
Services
Integrated preclinical development services including efficacy testing in animal models, safety/toxicology studies, immunogenicity assays, biomarker analyses, and data package preparation to support IND submissions.
Design and conduct of Phase I clinical trials including protocol implementation, enrollment, dosing, safety monitoring, and immunogenicity assessment for vaccine candidates.
Coordination and oversight of clinical-grade recombinant protein manufacture and formulation under cGMP using external manufacturing partners to supply material for human trials.
Strategic support for licensing negotiations, co-development agreements and sublicensing arrangements to enable platform commercialization and partner collaborations.
Integrated preclinical development services including efficacy testing in animal models, safety/toxicology studies, immunogenicity assays, biomarker analyses, and data package preparation to support IND submissions.
Design and conduct of Phase I clinical trials including protocol implementation, enrollment, dosing, safety monitoring, and immunogenicity assessment for vaccine candidates.
Coordination and oversight of clinical-grade recombinant protein manufacture and formulation under cGMP using external manufacturing partners to supply material for human trials.
Strategic support for licensing negotiations, co-development agreements and sublicensing arrangements to enable platform commercialization and partner collaborations.
Expertise Areas
- Epitope-based antigen design and multi-epitope carrier engineering
- Multi-modality vaccine development (DNA, recombinant protein, mRNA)
- Preclinical efficacy and IND-enabling safety testing in neurodegenerative disease models
- Immunoassay development and neuropathology biomarker quantification
Key Technologies
- Multi-epitope T-helper carrier platforms
- Epitope-based recombinant protein vaccines
- DNA vaccine constructs
- mRNA vaccine platforms
News & Updates
Nuravax's vaccine targeting amyloid-beta has shown to be safe and immunogenic in Phase 1 trials, indicating promising progress in Alzheimer's vaccine development.
The FDA has cleared the first blood test for diagnosing Alzheimer's, supporting early detection efforts which are crucial for vaccine and therapy development.
Nuravax's vaccine AV-1959R has entered human trials with the goal of preventing Alzheimer's disease before symptoms appear.
Nuravax has licensed the MultiTEP vaccine platform technology from the Institute for Molecular Medicine, enabling development of vaccines targeting amyloid-beta and tau proteins in Alzheimer's disease.
Nuravax has developed a broad spectrum of vaccines for neurodegenerative diseases using the MultiTEP platform, including vaccines for Alzheimer's, tauopathies, Parkinson's, and COVID-19.
Nuravax utilizes the MultiTEP platform to develop vaccines that generate high antibody levels against toxic proteins involved in neurodegenerative diseases.
Nuravax's vaccine targeting amyloid-beta has shown to be safe and immunogenic in Phase 1 trials, indicating promising progress in Alzheimer's vaccine development.
The FDA has cleared the first blood test for diagnosing Alzheimer's, supporting early detection efforts which are crucial for vaccine and therapy development.
Nuravax's vaccine AV-1959R has entered human trials with the goal of preventing Alzheimer's disease before symptoms appear.
Nuravax has licensed the MultiTEP vaccine platform technology from the Institute for Molecular Medicine, enabling development of vaccines targeting amyloid-beta and tau proteins in Alzheimer's disease.
Nuravax has developed a broad spectrum of vaccines for neurodegenerative diseases using the MultiTEP platform, including vaccines for Alzheimer's, tauopathies, Parkinson's, and COVID-19.
Nuravax utilizes the MultiTEP platform to develop vaccines that generate high antibody levels against toxic proteins involved in neurodegenerative diseases.